GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Land And Improvements

Theranexus (XPAR:ALTHX) Land And Improvements : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Theranexus Land And Improvements?

Theranexus's land and improvements for the quarter that ended in Dec. 2023 was €0.00 Mil.


Theranexus Land And Improvements Historical Data

The historical data trend for Theranexus's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus Land And Improvements Chart

Theranexus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial Premium Member Only - - - - -

Theranexus Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Theranexus Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Theranexus (XPAR:ALTHX) Business Description

Traded in Other Exchanges
Address
60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines